Nadofaragene Firadenovec Delivers Durable Responses in Bladder Cancer
Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.